使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings. Welcome to the Align Q2 '22 earnings call. (Operator Instructions) Please note this conference is being recorded.
各位好,歡迎參加 Align 2022 年第二季(Q2 '22)財報電話會議。(接線員指示)請注意,本次會議將被錄音。
I will now turn the conference over to your host, Shirley Stacy, with Align Technology. You may begin.
現在我將把會議交給本次會議主持人、Align Technology 的 Shirley Stacy。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.
各位下午好,感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。
We issued second quarter 2022 financial results today via Business Wire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on August 10.
我們今天已透過 Business Wire 發布 2022 年第二季財務結果,並可於我們網站 investor.aligntech.com 取得。今天的電話會議將以音訊方式網路直播,並將在我們網站上存檔約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,並持續至 8 月 10 日美東時間下午 5:30。
To access as a telephone replay, domestic callers should dial (866) 813-9403 with access code 137829. International callers should dial (929)458-6194 using the same access code.
如需以電話方式收聽重播,美國境內來電者請撥打 (866) 813-9403,並輸入存取碼 137829。國際來電者請撥打 (929)458-6194,並使用相同存取碼。
As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions, and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天提供並討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件及產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會(SEC)提交的定期報告中更詳細說明,該等文件可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We have posted historical financial statements, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our second quarter 2022 conference call slides on our website under quarterly results. Please refer to these files for more detailed information.
我們已在網站「季度結果」專區發布歷史財務報表及相對應的調節表(如適用,包括 GAAP 與非 GAAP 的調節),以及 2022 年第二季電話會議簡報。請參閱這些檔案以取得更詳細資訊。
And with that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我想把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide an overview of our Q2 results and discuss the performance of our 2 operating segments, Systems and Services and Clear Aligners. John will provide more detail on our financial performance and our view for the remainder of the year. Following that, I'll come back and summarize a few key points and open the call to questions.
謝謝你,Shirley。各位下午好,感謝各位加入。今天的電話會議上,我將概述我們第二季(Q2)業績,並討論兩個營運部門——系統與服務(Systems and Services)以及透明牙套(Clear Aligners)的表現。John 將更詳細說明我們的財務表現以及對今年剩餘期間的看法。之後我會回來總結幾個重點,並開放提問。
I'm pleased to report solid second quarter results with top line revenues relatively unchanged from Q1, and an operating margin of approximately 20%, despite unfavorable foreign exchange. The underlying market for orthodontics continues to be impacted by macroeconomic environment factors and lingering effects of COVID-19 variants in certain markets.
我很高興報告第二季交出穩健成果:儘管外匯不利影響,營收(top line)與第一季(Q1)相比大致持平,營業利益率約為 20%。矯正市場的基本面仍持續受到總體經濟環境因素以及部分市場 COVID-19 變異株餘波的影響。
Notwithstanding these headwinds, we've remained focused on achieving our strategic initiatives, including opening new offices in the Middle East and Africa and our new manufacturing facility in Poland, launching new solutions to better support the way our customers want to do business. such as a Doctor Subscription Program, and Teen case packs, and announcing new products and innovation to help our doctors and their patients. These new innovations are revolutionizing the digital treatment planning and helping to drive the evolution of digital orthodontics and comprehensive dentistry.
儘管面臨這些逆風,我們仍專注於推動策略性計畫,包括在中東與非洲設立新辦公室,以及在波蘭啟用新的製造設施;並推出新方案以更好支援客戶偏好的交易方式,例如醫師訂閱方案(Doctor Subscription Program)與青少年病例套裝(Teen case packs);同時宣布新產品與創新,以協助醫師及其病患。這些新創新正在革新數位治療規劃,並有助推動數位矯正與全方位牙科的演進。
Align is well positioned to withstand the current market conditions to lead a digital revolution in orthodontics and dentistry as the environment and growth trends improve. For Systems and Services , Q2 revenues were up 4.7% sequentially and up slightly year-over-year compared to Q2 '21 year-over-year growth of 215%. Q2 Systems and Services revenues increased sequentially driven by scanner volume growth in the Americas and APAC, partially offset by lower volume in EMEA, and unfavorable impact of foreign exchange. The iTero Element 5D imaging system continues to represent the majority of our scanner volume as doctors recognize the benefits of going digital.
Align 具備良好條件以因應目前市場狀況,並在環境與成長趨勢改善時,引領矯正與牙科的數位革命。就系統與服務部門而言,第二季營收較前一季成長 4.7%,與去年同期相比小幅成長;相較之下,2021 年第二季(Q2 '21)年增率為 215%。第二季系統與服務營收的季增主要由美洲與亞太(APAC)掃描器出貨量成長帶動,但部分被歐洲、中東與非洲(EMEA)較低的出貨量以及外匯不利影響所抵銷。iTero Element 5D 影像系統仍占我們掃描器出貨量的大宗,因為醫師逐漸認知到數位化的效益。
In APAC, the iTero entry-level Flex scanner offering was up sequentially in Q2, reflecting increased adoption. I'm also pleased with sequentially increasing services revenues in Q2, reflecting growth from the installed base. Services revenues represent approximately 40% of our Systems and Services business. For our Clear Aligner segment, Q2 revenues were down slightly sequentially and down 5.1% year-over-year compared to our Q2 '21 record year-over-year revenue growth of 182%.
在亞太地區,iTero 入門級 Flex 掃描器產品於第二季較前一季成長,反映採用率提升。我也對第二季服務營收的季增感到滿意,顯示已安裝基礎(installed base)帶來的成長。服務營收約占我們系統與服務業務的 40%。至於透明牙套部門,第二季營收較前一季小幅下滑,且年減 5.1%;相較之下,我們在 2021 年第二季(Q2 '21)創下年增 182% 的營收成長紀錄。
For the quarter, Q2 Clear Aligner volumes reflect sequential growth across the Americas and parts of EMEA, partially offset by China and U.K. Q2 Invisalign case starts for teens and younger patients was 177,300 up slightly sequentially and down 2.1% year-over-year compared to Q2 last year when our Teen case shipment growth rate was an all-time high. For Q2, Invisalign First for kids as young as 6 years old, grew year-over-year and was strong across all regions.
就本季而言,第二季透明牙套出貨量在美洲及 EMEA 的部分地區呈現季增,但被中國與英國的表現部分抵銷。第二季青少年與更年輕患者的 Invisalign 病例啟動數(case starts)為 177,300,較前一季小幅增加,但較去年同期年減 2.1%;去年第二季我們的青少年病例出貨成長率曾達歷史新高。第二季方面,適用於最小 6 歲兒童的 Invisalign First 年增成長,且在所有地區表現強勁。
During Q2, we introduced Invisalign Teen packs in the U.S. and Canada and France. Teen packs is our new subscription program, which enables orthodontists to buy clear aligners and packs in advance, similar to the way they buy wires and brackets today. Our Teen case pack simplified the ordering process and make the billing more predictable for doctors. Teen case packs also include exclusive practice development benefits with the Invisalign brand and requires an incremental volume commitment from doctors.
在第二季期間,我們於美國、加拿大與法國推出 Invisalign 青少年套裝(Invisalign Teen packs)。Teen packs 是我們新的訂閱方案,使矯正醫師能預先購買透明牙套與套裝,類似於他們目前購買鋼絲與托槽的方式。我們的青少年病例套裝簡化了下單流程,並讓醫師的帳務更可預測。青少年病例套裝亦包含 Invisalign 品牌的專屬診所發展(practice development)效益,並要求醫師承諾額外的出貨量。
To date, enrollment has been encouraging with early adoptions highest among doctors who have not historically used Invisalign aligners to treat their teen patients. For other non-case revenues, which include retention products such as Vivera Retainers, clinical training and education, accessories, e-commerce and our new subscription programs such as our DSP revenues, were up both sequentially and year-over-year. For retainers, Q2 shipments had strong momentum with sequential and year-over-year growth across all regions driven by both submitters and utilization.
截至目前,報名情況令人鼓舞,早期採用者以過去並未經常使用 Invisalign 牙套治療青少年患者的醫師為最多。至於其他非病例營收(non-case revenues),包括 Vivera 維持器(Vivera Retainers)等維持產品、臨床訓練與教育、配件、電商,以及我們新的訂閱方案(例如 DSP 營收),無論季比或年比皆成長。就維持器而言,第二季出貨動能強勁,所有地區均呈現季增與年增,成長動能同時來自提交者(submitters)增加與使用率(utilization)提升。
Momentum in our Doctor Subscription Program continued and Q2 revenues increased over 60% sequentially.
我們的醫師訂閱方案(Doctor Subscription Program)動能持續,第二季營收較前一季成長超過 60%。
Now let's turn to the specifics around our second quarter results, starting with the Americas. For the Americas region, Q2 Invisalign case volumes were up sequentially, reflecting increased submissions from the orthodontic channel and increased utilization from the GP channel. From a product standpoint, Q2 sequential Invisalign case growth reflects increases in both comprehensive and noncomprehensive products, including Invisalign First and Invisalign Moderate. Q2 also benefited from increased utilization in the DSO channel.
接下來我們來看第二季業績的細節,先從美洲開始。美洲地區第二季 Invisalign 病例量較前一季增加,反映矯正通路提交量提升,以及一般牙醫(GP)通路使用率提高。從產品面來看,第二季 Invisalign 病例的季增反映綜合型(comprehensive)與非綜合型(noncomprehensive)產品皆成長,包括 Invisalign First 與 Invisalign Moderate。第二季亦受惠於牙科服務組織(DSO)通路使用率提升。
Our international Clear Aligners, Q2 Invisalign case volumes were down 1.7% sequentially, primarily as a result of the headwinds described previously. For EMEA, Q2 Invisalign case volumes were down slightly primarily reflecting a slight increase in Iberia and Italy, offset primarily by slightly lower sequential volumes in the U.K. and France. For Q2, expansion market shipments declined sequentially. Q2 Invisalign teen patients increased sequentially driven by an increase in the number of doctors submitting teen cases.
在國際透明牙套業務方面,第二季 Invisalign 病例量較前一季下滑 1.7%,主要因前述逆風所致。就 EMEA 而言,第二季 Invisalign 病例量小幅下滑,主要反映伊比利亞與義大利略有增加,但主要被英國與法國較前一季略低的病例量所抵銷。第二季擴張市場(expansion markets)出貨量較前一季下降。第二季 Invisalign 青少年患者數較前一季增加,主要由提交青少年病例的醫師數量增加所帶動。
Turning to APAC. Invisalign case volumes were down slightly, reflecting a full quarter effect of continued lockdowns in China. For Q2, Taiwan, Hong Kong, Japan and India performed well during the quarter. On a year-over-year basis, Invisalign case shipments growth was strong in Japan, India, Taiwan, Thailand and Korea. The APAC teen case volume increased year-over-year, primarily driven by increased doctor submitters.
再看亞太(APAC)。Invisalign 病例量小幅下滑,反映中國持續封控的影響在第二季呈現完整季度效應。第二季期間,台灣、香港、日本與印度表現良好。以年比來看,日本、印度、台灣、泰國與韓國的 Invisalign 病例出貨成長強勁。亞太地區青少年病例量年增,主要由提交病例的醫師數增加所帶動。
Turning to new innovations. The Align Digital Platform is an integrated suite of proprietary technologies and services delivered as a seamless end-to-end solution to customers that connects all users, doctors, labs patients and consumers to transform smiles, and change lives. Our technology advancements help our doctor customers deliver superior clinical outcomes, treatment efficiency and also superior patient experience.
接下來談新創新。Align 數位平台(Align Digital Platform)是一套整合式的專有技術與服務組合,以無縫的端到端解決方案交付給客戶,連結所有使用者——醫師、技工所、患者與消費者——以改變笑容並改變人生。我們的技術進展協助醫師客戶提供更優異的臨床結果、治療效率,以及更佳的患者體驗。
In Q2, we introduced Invisalign Outcome Simulator Pro and Cone Beam Computed Tomography systems integration for ClinCheck software, building on several new innovations announced last quarter that we'll begin rolling out across the regions in August. Invisalign Outcome Simulator Pro, the next-generation patient communication tool that empowers doctors to help patients visualize their potential new smile after Invisalign treatment. Use in-phase visualization in 3D dentition view, all done chairside in minutes.
在第二季,我們推出 Invisalign Outcome Simulator Pro,以及針對 ClinCheck 軟體的錐形束電腦斷層(Cone Beam Computed Tomography, CBCT)系統整合;這是建立在上季宣布的多項新創新之上,我們將自 8 月起開始在各地區逐步推出。Invisalign Outcome Simulator Pro 是新一代的患者溝通工具,讓醫師能協助患者視覺化其在 Invisalign 治療後可能呈現的新笑容。可在 3D 牙列視圖中進行分階段(in-phase)視覺化,並可在診間於數分鐘內完成。
Cone Beam Computed Tomography systems, or what we call CBCT, integration for ClinCheck software is designed to deliver a complete view of a patient's roots, crown and jawbone. CBCT integration for ClinCheck software enables doctors to confidently deliver a more informed Invisalign clear liner treatment plan or a wide range of cases. The user-friendly interface makes it easy for doctors to see their patients root, crown and jawbone and 1 automatically digitally fused 3D model. This allows doctors to tailor their treatment, plan based on their experience and their patients' needs. CBCT integration for ClinCheck software gives doctors the control and confidence to expand treatment planning to a broad range of mal inclusions, including surgical, restorative, expansion, extraction as well as teen cases with impacted or unerupted teeth.
錐形束電腦斷層掃描系統(Cone Beam Computed Tomography,簡稱 CBCT)與 ClinCheck 軟體的整合,旨在提供患者牙根、牙冠與顎骨的完整視圖。ClinCheck 軟體的 CBCT 整合使醫師能更有信心地制定更充分資訊的 Invisalign 隱形牙套治療計畫,並可涵蓋更廣泛的病例。其易用的介面讓醫師能輕鬆查看患者的牙根、牙冠、顎骨,以及 1 個自動完成數位融合的 3D 模型。這使醫師能依其經驗與患者需求量身調整治療計畫。ClinCheck 軟體的 CBCT 整合讓醫師具備掌控力與信心,將治療規劃擴展至更廣泛的咬合不正類型,包括外科、修復、擴弓、拔牙,以及具有阻生或未萌出牙齒的青少年病例。
While it's still early in the commercialization of these new products, initial feedback from doctors is encouraging. We are excited to begin scaling them across our customer base in the second half of 2022. Also, during the quarter, we awarded 11 new research grants totaling $275,000 to universities around the world. Through our annual research awards program, we help advance orthodontic and dental research, furthering our commitment to the future of digital orthodontics and restorative dentistry.
儘管這些新產品的商業化仍處於早期階段,醫師的初步回饋令人鼓舞。我們很期待在 2022 年下半年開始在客戶群中擴大推廣。此外,本季度我們向全球各地的大學頒發了 11 項新的研究補助,總額 275,000 美元。透過我們的年度研究獎助計畫,我們協助推進齒顎矯正與牙科研究,進一步落實我們對數位矯正與修復牙科未來的承諾。
Our consumer marketing is focused on educating consumers about the Invisalign system, and driving that demand to Invisalign doctors offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles. For Q2, we had over 16.2 million visits to our websites, a 15% year-over-year increase, and delivered over 6.3 billion impressions. Both metrics were lower versus Q1 as we chose to rightsize our size and media spend in Q2 given the macroeconomic environment.
我們的消費者行銷聚焦於教育消費者了解 Invisalign 系統,並將需求導向 Invisalign 醫師診所,最終把握轉變 5 億個笑容的龐大市場機會。第二季,我們網站的造訪次數超過 1,620 萬次,年增 15%,並投放超過 63 億次曝光。由於宏觀經濟環境,我們在第二季選擇調整規模並縮減媒體支出,因此這兩項指標均較第一季下降。
During the quarter, we built on our successful "Invis is" multimedia campaign and launched in the U.S. the next evolution with 2 new campaigns, "Invis is trauma-free", targeted at teens, and "Invis is when everything clicks", targeted at adults. Our Invis is trauma-free campaign highlights the benefits of Invisalign treatment, while numerously juxtaposing teens with the significant hassles involved with using braces. Our Invis is when everything clicks campaign showcases of Invisalign treatment transforming smiles and the resulting confidence it gives to young adults. Both campaigns will be rolled out to markets around the world in Q3.
本季度,我們在成功的「Invis is」多媒體活動基礎上持續推進,並在美國推出下一階段的 2 個新活動:「Invis is trauma-free」,鎖定青少年;以及「Invis is when everything clicks」,鎖定成人。我們的「Invis is trauma-free」活動強調 Invisalign 治療的優點,同時多次對比青少年使用傳統牙套所帶來的重大不便。我們的「Invis is when everything clicks」活動則展示 Invisalign 治療如何改變笑容,以及它為年輕成人帶來的自信。兩個活動都將在第三季推廣至全球各市場。
Advancing of our consumer patient app, My Invisalign, continued to increase with 1.8 million downloads to date. Uses of our 4 digital tools continues to increase, for example, Invisalign virtual appointment tool was used over 12,000 times, and our insurance verification feature was used 36,000 times in Q2. Further, we received more than 91,000 patient photos in our virtual care feature globally, which continues to provide us with rich data to leverage our artificial intelligence capabilities and improve our services for doctors and patients. Additional consumer demand metrics are included in our Q2 earnings slides posted on our website.
我們持續推進消費者患者 App「My Invisalign」,截至目前下載量已達 180 萬次。我們的 4 項數位工具使用量持續增加,例如 Invisalign 線上預約工具使用超過 12,000 次,而保險驗證功能在第二季使用 36,000 次。此外,我們在全球的虛擬照護功能中收到超過 91,000 張患者照片,這些資料持續為我們提供豐富數據,以運用人工智慧能力並改善對醫師與患者的服務。更多消費者需求指標已包含在我們網站上發布的第二季財報簡報中。
We are pleased with our Q2 Systems and Services revenues, which were up 5% sequentially and up 1% year-over-year. Q2 sequential growth primarily reflects higher scanner volumes in the Americas and APAC, in increased subscriptions. Year-over-year results primarily reflect increased scanner revenues in the Americas, offset by lower volume in APAC and EMEA. Growth of our iTero scanner installed base is driving an increase in services revenue.
我們對第二季系統與服務(Systems and Services)營收感到滿意,該營收較前一季成長 5%,較去年同期成長 1%。第二季的季增主要反映美洲與亞太地區(APAC)掃描器出貨量較高,以及訂閱增加。年增結果主要反映美洲掃描器營收增加,但被亞太與歐洲、中東及非洲(EMEA)地區較低的出貨量所抵銷。我們 iTero 掃描器裝機基數的成長正帶動服務營收增加。
On a year-over-year basis, Systems and Services growth reflects increased service revenues from our largest scanner installed base, higher subscription revenues and increased sales of scanner once leased. The number of intraoral digital scans used for Invisalign case submissions in Q2 reflect continued adoption of our digital scanners and our larger installed base. Total worldwide intraoral digital scan submitted to start an Invisalign case in Q2 increased 88.4% from 82.2% in Q2 of last year.
以年增角度來看,系統與服務的成長反映來自我們最大掃描器裝機基數的服務營收增加、訂閱營收提高,以及先前租賃之掃描器的銷售增加。第二季用於 Invisalign 病例提交的口內數位掃描數量,反映我們數位掃描器持續被採用以及裝機基數擴大。第二季全球用於啟動 Invisalign 病例的口內數位掃描提交占比提升至 88.4%,高於去年第二季的 82.2%。
International intraoral digital scans for Invisalign case submissions increased 84.4%, up from 76.2% in Q2 of last year. For the Americas, 91.4% of Invisalign cases were submitted using an intraoral digital scan compared to 87% in Q2 last year. Cumulatively, over 60.4 million orthodontic scans and over 12.6 million restorative scans have been performed with iTero scanners.
國際市場用於 Invisalign 病例提交的口內數位掃描占比提升至 84.4%,高於去年第二季的 76.2%。在美洲,第二季有 91.4% 的 Invisalign 病例使用口內數位掃描提交,相較去年第二季的 87% 提升。累計而言,使用 iTero 掃描器已完成超過 6,040 萬次矯正掃描與超過 1,260 萬次修復掃描。
Our Q2 exocad CAD/CAM products and services, which include restorative dentistry, implantology, guided surgery and smile design offerings are included in our Systems and Services revenue. Exocad products and services are helping extend our digital dental solutions and broaden the aligned digital platform towards fully integrated interdisciplinary end-to-end workflows. During the quarter, exocad released dental CAD 3.1 Rijeka in the new powerful lab software, which saves design time and offers more intuitive workflows along the designs earning from CAD to CAM.
我們第二季的 exocad CAD/CAM 產品與服務(涵蓋修復牙科、植牙學、導引手術與微笑設計等方案)納入系統與服務營收。Exocad 的產品與服務正協助延伸我們的數位牙科解決方案,並將一致的數位平台拓展至完全整合的跨專科端到端工作流程。本季度,exocad 在其全新且強大的技工所軟體中發布 dental CAD 3.1 Rijeka,可節省設計時間,並提供更直覺的工作流程,涵蓋從 CAD 到 CAM 的設計流程。
In addition, the release -- the exocad release launched the new, myexocad, portal, introducing mandatory end-user software use registration that for the first time, allows exocad to collect information about who and how customers are using the software. This expands the opportunities for future product improvements. Also during the quarter, we signed a new long-term contract with exocad largest customer, (inaudible), further strengthening our relationship.
此外,該次發布——exocad 發布了全新的 myexocad 入口網站,導入強制性的終端使用者軟體使用註冊,這使 exocad 首次能收集關於客戶是誰以及如何使用軟體的資訊,進而擴大未來產品改進的機會。同樣在本季度,我們與 exocad 最大客戶(聽不清)簽署新的長期合約,進一步強化我們的合作關係。
Finally, we continue to execute our strategy of geographic expansion. In June, our European manufacturing facility in Wroclaw, Poland, began manufacturing clear aligners for the EMEA region, locally, for the first time. We also continued our operational expansion in Poland with our latest treatment planning facility.
最後,我們持續執行地理擴張策略。6 月,我們位於波蘭弗羅茨瓦夫(Wroclaw)的歐洲製造工廠首次開始在當地為 EMEA 地區生產隱形牙套。我們也透過最新的治療規劃設施,持續擴大在波蘭的營運規模。
Our expanded operation in Poland supports Invisalign doctors in local languages, increases our flexibility and timeliness in supporting our doctor customers across the region, and we expect will positively influence the quality and time of preparation of ClinCheck treatment plans and provide our doctor customers with benefits of digital orthodontics with the Invisalign system. We are uniquely positioned with manufacturing and treatment planning in all 3 regions, and no other clear aligner manufacturer has our global footprint and capabilities.
我們在波蘭擴大的營運可用當地語言支援 Invisalign 醫師,提升我們在整個區域支援醫師客戶的彈性與即時性;我們預期這將對 ClinCheck 治療計畫的準備品質與時間產生正面影響,並讓醫師客戶享有 Invisalign 系統所帶來的數位矯正效益。我們在三大區域皆具備製造與治療規劃能力,具備獨特優勢,且沒有其他隱形牙套製造商擁有我們這樣的全球佈局與能力。
With that, I'll now turn the call over to John.
接下來,我把電話交給 John。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Thanks, Joe. Now for our Q2 financial results. Total revenues for the second quarter were $969.6 million, down 0.4% from the prior quarter and down 4.1% from the corresponding quarter a year ago. This is compared to Q2 '21 revenues of $1 billion, which had a year-over-year growth rate of 186.9%. For clear aligners, Q2 revenues of $798.4 million were down 1.4% sequentially, due primarily to product mix and unfavorable foreign exchange, partially offset by higher non-case revenues, and down 5.1% year-over-year, primarily reflecting lower volumes, unfavorable impact from foreign exchange and product mix shift, partially offset by higher additional aligners, per order processing fees and higher non-case revenues.
謝謝,Joe。接著說明我們第二季的財務結果。第二季總營收為 969.6 百萬美元,較前一季下降 0.4%,較去年同期下降 4.1%。相較之下,2021 年第二季營收為 10 億美元,年增率為 186.9%。就隱形牙套而言,第二季營收為 798.4 百萬美元,較前一季下降 1.4%,主要因產品組合與不利的外匯影響,部分被較高的非病例(non-case)營收所抵銷;較去年同期下降 5.1%,主要反映出貨量較低、外匯不利影響與產品組合轉移,部分被每筆訂單的額外牙套、處理費以及較高的非病例營收所抵銷。
Q2 '22 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $12.3 million or approximately 1.5% sequentially, and approximately $32.9 million or approximately 4% year-over-year. For Q2, Invisalign comprehensive ASPs decreased sequentially and increased year-over-year. On a sequential basis, the decline in comprehensive ASPs reflect higher discounts and unfavorable impact from foreign exchange, partially offset by higher additional aligners.
2022 年第二季隱形牙套營收受到外匯不利影響:較前一季約 12.3 百萬美元(約 1.5%),較去年同期約 32.9 百萬美元(約 4%)。第二季 Invisalign 全方案(comprehensive)ASP 較前一季下降、較去年同期上升。就季比而言,全方案 ASP 的下降反映折扣增加與外匯不利影響,部分被較高的額外牙套所抵銷。
On a year-over-year basis, higher comprehensive ASPs reflect the impact of higher additional aligners and per order processing fees, partially offset by the impact of unfavorable foreign exchange and higher discounts. Q2 Invisalign noncomprehensive ASPs increased sequentially and year-over-year.
就年比而言,全方案 ASP 較高反映額外牙套增加與每筆訂單處理費提高的影響,部分被外匯不利影響與折扣增加所抵銷。第二季 Invisalign 非全方案(noncomprehensive)ASP 較前一季及較去年同期均上升。
On a sequential basis, Invisalign noncomprehensive ASPs were favorably impacted by lower discounts, partially offset by product mix and unfavorable foreign exchange. On a year-over-year basis, higher Invisalign noncomprehensive ASPs reflect lower discounts, per order processing fees and higher additional aligners, partially offset by the impact of unfavorable foreign exchange and product mix shift.
就季比而言,Invisalign 非全方案 ASP 受較低折扣的有利影響,部分被產品組合與外匯不利影響所抵銷。就年比而言,Invisalign 非全方案 ASP 較高反映折扣較低、每筆訂單處理費以及額外牙套增加,部分被外匯不利影響與產品組合轉移所抵銷。
Clear Aligner of deferred revenues on the balance sheet increased $25.4 million or 2.3% sequentially and $231 million or up 25.5% year-over-year, and will be recognized as the additional aligners are shipped. Q2 '22 Systems and Services revenue of $171.2 million were up 4.7% sequentially, primarily due to higher scanner volume and ASP, and were up slightly by 0.8% year-over-year, primarily from higher services revenues from our larger installed base, partially offset by lower scanner volume and lower ASP.
資產負債表上的隱形牙套遞延營收(deferred revenues)較前一季增加 25.4 百萬美元(2.3%),較去年同期增加 231 百萬美元(成長 25.5%),並將在額外牙套出貨時認列。2022 年第二季系統與服務營收為 171.2 百萬美元,較前一季成長 4.7%,主要因掃描器出貨量與 ASP 較高;較去年同期小幅成長 0.8%,主要來自較大裝機基數帶動的服務營收增加,部分被掃描器出貨量較低與 ASP 較低所抵銷。
Systems and Services revenue were unfavorably impacted by foreign exchange of approximately $2.9 million, or approximately 1.7% sequentially. On a year-over-year basis, Systems and Services revenue were unfavorably impacted by foreign exchange of approximately $7 million or approximately 3.9%. Systems and Services deferred revenues on the balance sheet was $13.3 million or 5.4% sequentially, and up $99.6 million or 62.3% year-over-year primarily due to the increase in scanner sales and the deferral of service revenues included with the scanner purchase, which will be recognized ratably over the service period.
系統與服務營收受到外匯不利影響約 290 萬美元,約為季比 1.7%。以年比來看,系統與服務營收受到外匯不利影響約 700 萬美元,約為 3.9%。資產負債表上的系統與服務遞延收入為 1,330 萬美元,季比增加 5.4%,且年比增加 9,960 萬美元或 62.3%,主要由於掃描儀銷售增加,以及隨掃描儀購買所包含之服務收入予以遞延,該等收入將於服務期間按比例認列。
Moving on to gross margin. Second quarter overall gross margin was 70.9%, down 2 points sequentially and down 4.1 points year-over-year. Overall, gross margin was unfavorably impacted by approximately 0.5 points sequentially and 1.1 points on a year-over-year basis due to foreign exchange. Clear Aligner gross margin for the second quarter was 73.3%, down 1.5 points sequentially due to lower ASPs and higher freight costs. Clear Aligner gross margin was down 3.6 points year-over-year due to a higher mix of additional aligner volume, higher freight and manufacturing spend, partially offset by higher ASPs.
接著談毛利率。第二季整體毛利率為 70.9%,季比下降 2 個百分點,年比下降 4.1 個百分點。整體而言,毛利率因外匯因素而受到不利影響:季比約 0.5 個百分點、年比約 1.1 個百分點。第二季透明矯正器毛利率為 73.3%,因平均銷售價格(ASP)較低及運費成本較高,季比下降 1.5 個百分點。透明矯正器毛利率年比下降 3.6 個百分點,原因為額外矯正器出貨量占比提高、運費及製造支出增加,部分被較高的 ASP 所抵銷。
Systems and Services gross margin for the second quarter was 59.8%, down 3.6 points sequentially due to higher manufacturing variances and freight costs partially offset by higher ASPs. Systems and Services gross margin was down 6.1 points year-over-year due to lower ASPs and higher manufacturing variances, partially offset by higher service mix.
第二季系統與服務毛利率為 59.8%,因製造差異較高及運費成本增加,部分被較高的 ASP 抵銷,季比下降 3.6 個百分點。系統與服務毛利率年比下降 6.1 個百分點,原因為 ASP 較低及製造差異較高,部分被服務組合占比提高所抵銷。
Q2 operating expenses were $499.4 million, down sequentially 2.3% and up 2% year-over-year. On a sequential basis, operating expenses were down by $11.9 million mainly due to lower incentive compensation and controlled spend on advertising and marketing as part of our efforts to proactively manage costs. Year-over-year, operating expenses increased by $9.7 million, reflecting our continued investment in marketing, sales and R&D activities and investments commensurate with business growth.
第二季營業費用為 4.994 億美元,季比下降 2.3%,年比上升 2%。就季比而言,營業費用減少 1,190 萬美元,主要因獎勵性薪酬較低,以及作為我們主動管理成本努力的一部分,對廣告與行銷支出加以控管。就年比而言,營業費用增加 970 萬美元,反映我們持續投資於行銷、銷售與研發活動,以及與業務成長相稱的投資。
On a non-GAAP basis, excluding stock-based compensation, amortization of acquired intangibles related to certain acquisitions and acquisition costs, operating expenses were $466 million down sequentially 3% and up 1% year-over-year. Our second quarter operating income of $188.2 million resulted in an operating margin of 19.4%, down 0.9 points sequentially and down 7.2 points year-over-year. Operating margin was unfavorably impacted by approximately 1.1 points sequentially due to foreign exchange. The year-over-year decrease in operating margin is primarily attributable to lower gross margin, investments in our go-to-market teams and technology as well as unfavorable impact from foreign exchange by approximately 2.4 points.
以非 GAAP 基礎計算(排除股份基礎給付、與特定收購相關之取得無形資產攤銷及收購成本),營業費用為 4.66 億美元,季比下降 3%,年比上升 1%。第二季營業利益為 1.882 億美元,營業利益率為 19.4%,季比下降 0.9 個百分點,年比下降 7.2 個百分點。營業利益率因外匯因素而季比受到約 1.1 個百分點的不利影響。營業利益率年比下降主要歸因於毛利率較低、對我們市場拓展(go-to-market)團隊與技術的投資,以及外匯不利影響約 2.4 個百分點。
On a non-GAAP basis, which excludes stock-based compensation, amortization of intangibles related to certain acquisitions and acquisition costs, operating margin for the second quarter was 23.3%, down 0.7 points sequentially and down 6.5 points year-over-year.
以非 GAAP 基礎計算(排除股份基礎給付、與特定收購相關之無形資產攤銷及收購成本),第二季營業利益率為 23.3%,季比下降 0.7 個百分點,年比下降 6.5 個百分點。
Interest and other income expense net for the second quarter was a loss of $14.6 million, down sequentially by $4 million and down year-over-year by $14.5 million, primarily due to larger net foreign exchange losses from the weakening of certain foreign currencies against the U.S. dollar.
第二季利息及其他損益淨額為虧損 1,460 萬美元,季比減少 400 萬美元,年比減少 1,450 萬美元,主要由於部分外幣兌美元走弱導致淨外匯損失增加。
The GAAP effective tax rate in the second quarter was 35% compared to 28.4% in the first quarter and 25.7% in the second quarter of the prior year. Our non-GAAP effective tax rate was 25.6% in the second quarter compared to 24.2% in the first quarter and 19.5% in the second quarter of the prior year. The second quarter GAAP effective tax rate was higher than the first quarter effective tax rate primarily due to foreign income tax at different rates and lower excess tax benefits from stock-based compensation.
第二季 GAAP 有效稅率為 35%,相較第一季為 28.4%,去年同期第二季為 25.7%。第二季非 GAAP 有效稅率為 25.6%,相較第一季為 24.2%,去年同期第二季為 19.5%。第二季 GAAP 有效稅率高於第一季,主要因海外所得稅適用不同稅率,以及股份基礎給付帶來的超額稅務利益較低。
Second quarter net income per diluted share was $1.44, down sequentially $0.26 and down $1.07 compared to the prior year. Our EPS was unfavorably impacted by $0.26 on a sequential basis and $0.42 on a year-over-year basis due to foreign exchange. On a non-GAAP basis, net income per share was $2 for the second quarter, down $0.13 sequentially and down $1.04 year-over-year.
第二季稀釋後每股淨利為 1.44 美元,季比下降 0.26 美元,較去年同期下降 1.07 美元。由於外匯因素,我們的每股盈餘(EPS)季比受到 0.26 美元的不利影響,年比受到 0.42 美元的不利影響。以非 GAAP 基礎計算,第二季每股淨利為 2 美元,季比下降 0.13 美元,年比下降 1.04 美元。
Moving on to the balance sheet. As of June 30, 2022, cash, cash equivalents and short- and long-term marketable securities were $977.2 million, down sequentially $143.4 million and down $109.2 million year-over-year. Of our $977.2 million balance, $251.4 million was held in the U.S. and $725.8 million was held by our international entities.
接著看資產負債表。截至 2022 年 6 月 30 日,現金、約當現金以及短期與長期有價證券為 9.772 億美元,季比減少 1.434 億美元,年比減少 1.092 億美元。在 9.772 億美元餘額中,2.514 億美元持有於美國,7.258 億美元由我們的海外實體持有。
Q2 accounts receivable balance was $931.9 million, down approximately 2% sequentially. Our overall days sales outstanding was 85 days, down approximately 2 days sequentially and up approximately 13 days as compared to Q2 last year. Cash flow from operations for the second quarter was $127 million. Capital expenditures for the second quarter were $76 million, primarily related to our continued investments to increase aligner manufacturing capacity and facilities.
第二季應收帳款餘額為 9.319 億美元,季比下降約 2%。整體應收帳款週轉天數(DSO)為 85 天,季比減少約 2 天,較去年第二季增加約 13 天。第二季營運活動現金流量為 1.27 億美元。第二季資本支出為 7,600 萬美元,主要與我們持續投資以提升矯正器製造產能與設施相關。
Free cash flow, defined as cash flow from operations less capital expenditures amounted to $51 million. In Q2, we purchased $200 million of our common stock through an accelerated stock repurchase program, receiving approximately 757,000 shares at an average price of $264.37 per share. We are over halfway through our May 2021 $1 billion repurchase program, and have approximately $450 million remaining available for purchase.
自由現金流量(定義為營運活動現金流量扣除資本支出)為 5,100 萬美元。第二季我們透過加速股份回購計畫買回 2 億美元普通股,以每股平均 264.37 美元取得約 757,000 股。我們已完成 2021 年 5 月 10 億美元回購計畫的一半以上,目前仍有約 4.5 億美元可供回購。
Now turning to full year 2022 and the factors that influence our views on our business outlook. Overall, our Q2 results were solid, and we feel good about the execution across the business, especially in an increasingly challenging global economic environment. Delivering revenues and volumes relatively unchanged from Q1 and down only slightly year-over-year despite unfavorable impacts from foreign exchange speak to the strength of our underlying products and services and the size of our market opportunity. We remain confident in the huge underpenetrated market for digital orthodontics and restorative dentistry, our technology and our industry leadership and our ability to execute and make progress towards our long-term model of 20% to 30% revenue growth.
接著談 2022 全年以及影響我們對業務展望看法的因素。整體而言,我們第二季表現穩健,且對全公司各面向的執行感到滿意,尤其是在全球經濟環境日益具挑戰之際。儘管外匯帶來不利影響,我們的營收與出貨量相較第一季大致持平、年比僅小幅下降,顯示我們核心產品與服務的實力以及市場機會的規模。我們仍對數位正畸與修復牙科龐大且滲透率仍低的市場、我們的技術與產業領導地位,以及我們的執行能力充滿信心,並將持續朝長期模型所設定的 20% 至 30% 營收成長目標推進。
We also remain committed to our goal for fiscal 2022 to deliver GAAP operating margins above 20%, while making strategic investments in sales, marketing, R&D and operations, notwithstanding the impact from unfavorable foreign exchange, which was not factored into our operating margin guidance for the full year.
我們也仍致力於 2022 會計年度達成 GAAP 營業利益率高於 20% 的目標,同時在銷售、行銷、研發與營運方面進行策略性投資,儘管存在外匯不利影響,而該外匯影響並未納入我們全年營業利益率指引之中。
Capital expenditures primarily relate to building construction and improvements as well as a digital manufacturing capacity to support our international expansion. For 2022, we expect our investment in capital expenditures to exceed $300 million. This includes our investment in our aligner fabrication facility in Wroclaw, Poland.
資本支出主要與建築工程及改善,以及支援我們國際擴張的數位製造產能相關。對於 2022 年,我們預期資本支出投資將超過 3 億美元,其中包括我們對波蘭弗羅茨瓦夫(Wroclaw)矯正器製造設施的投資。
In times like these, our strong fundamental Business differentiates Align, and we are grateful to have a profitable underlying business model that generates strong cash flow as well as a healthy balance sheet that provides flexibility to invest in our growth while supporting our employees, customers and shareholders.
在這樣的時期,我們強健的基本面使 Align 脫穎而出;我們也很感謝能擁有一個具獲利能力的核心商業模式,能產生強勁現金流,以及健康的資產負債表,讓我們在支持員工、客戶與股東的同時,仍具備投資成長的彈性。
As we move into the second half of the year, we will continue to manage our investments to account for headwinds and uncertainty while focusing on successfully delivering on our strategic growth drivers.
隨著我們進入下半年,我們將持續管理各項投資,以因應逆風與不確定性,同時專注於成功推動我們的策略性成長驅動因素。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來我把時間交回給 Joe 做最後評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. Closing Q2 in the first half of 2022 has proved to be tougher than we expected. As we continue to navigate macroeconomic uncertainty and weaker consumer confidence and impacts related to COVID-19 variance, we cannot lose sight of the strong fundamentals of our business and the enormous market opportunity for digital orthodontics and restorative dentistry.
謝謝,John。2022 年上半年在第二季收官,結果證明比我們預期更艱難。當我們持續因應總體經濟不確定性、消費者信心轉弱,以及與 COVID-19 變異株相關的影響時,我們不能忽視公司業務的強健基本面,以及數位正畸與修復牙科所帶來的龐大市場機會。
The decisions we make this year will have lasting strategic implications for the future of our industry and the competitive landscape. We are holding true to our business strategy, and making good progress in a very difficult operating environment. We remain committed to balancing investments to drive growth and long-term strategic priorities with near-term headwinds while acting with a sense of urgency to ensure that we're ready to capitalize and extend our global innovation leadership as growth resumes.
我們今年所做的決策,將對本產業未來以及競爭格局產生長期的策略性影響。我們將堅守既定的業務策略,並在極為艱難的營運環境中取得良好進展。我們仍致力於在面對短期逆風的同時,平衡推動成長與長期策略優先事項所需的投資,並以高度緊迫感行動,確保在成長恢復時,我們已準備好把握機會並延伸我們在全球創新方面的領導地位。
Thanks for your time today. We look forward to updating you on our next earnings call.
感謝您今天撥冗參與。我們期待在下一次財報電話會議上向您更新最新進展。
With that, I'll turn it over to the operator. Operator?
接下來我把時間交給接線員。接線員?
Operator
Operator
(Operator Instructions) The first question is from Nathan Rich with Goldman Sachs.
(接線員指示)第一個問題來自高盛(Goldman Sachs)的 Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
I guess I wanted to start high level. Joe, you kind of highlighted the consistent kind of case in revenue trends in the second quarter relative to the first. But within the context of a challenging macro environment, I guess, how does that influence your thinking on the trajectory of the business? And have you seen an impact on patient traffic to dental practices or treatment acceptance rates that's kind of driving that commentary?
我想先從較高層次開始。Joe,你提到第二季相較第一季,營收趨勢呈現某種一致性。但在具挑戰性的總體環境下,這會如何影響你對業務走勢的看法?另外,你是否看到牙科診所的病患來診人流或治療接受率受到影響,進而驅動你剛才的評論?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Nate, it's a -- if you look at this from a domestic standpoint, you can pull out some signal, but I think you have to when you're asking a demand question like that, you have to look at this globally. And I think like John and I were just clear in our introduction that basically, if you took Asia, COVID-19 impacted us pretty tremendously in Asia. Japan for a little bit in the first part of the quarter and China almost throughout the quarter. So it was really a COVID discussion there, and it's hard to pull a demand signal out.
Nate,這個——如果從美國本土的角度來看,你可以抽取一些訊號,但我認為當你問的是這種需求問題時,你必須從全球角度來看。我想 John 和我在開場已經說得很清楚:如果看亞洲,COVID-19 對我們在亞洲的影響相當大。日本在本季前段受影響一段時間,而中國幾乎整個季度都受影響。所以那裡主要是 COVID 的討論,很難從中抽出需求訊號。
In the United States, I mean, if you look at the data that we do, you'll see from a general practitioner standpoint or whatever, some stability in patient vision to what's going on. Our concern here is, obviously, this is a product where -- like a cap or a crown or cleaning or something that needs to be done, it's somewhat discretionary. And we see that from an adult standpoint, more variability in adult selection than in teens. Teens have been pretty stable in that way if we talked about before.
在美國,我是說,如果你看我們所掌握的數據,從一般牙醫(general practitioner)等角度來看,病患就診情況相對穩定。我們的擔憂當然是,這類產品——例如牙套、牙冠、洗牙或其他需要處理的項目——在某種程度上屬於可選擇性支出。從成人端來看,我們看到成人選擇上的波動性比青少年更大。青少年在這方面一直相當穩定,正如我們之前談過的。
Moving over to Europe. We're working off 300% growth rates in Europe last year, okay, which you kind of have to internalize that. It's a pretty big comparison year-on-year. And there weren't standard vacations being taken in Europe to the beginning of the end of the second quarter and the third quarter.
再看歐洲。我們是以去年歐洲 300% 的成長率作為比較基期,好嗎,你必須把這點納入考量。這是一個非常大的年對年比較。另外,歐洲在第二季末到第三季初才開始出現較常態的度假季。
So overall, I'd say, as you look around the globe, I fee like -- I felt good, as we mentioned in the script, about Q1 versus Q2 and pretty much the same kind of demand pattern. But right now, I can't really give you a trajectory for the third quarter and the fourth quarter because of the macro environment, concerns again in China from another COVID shutdown and those types of things. I hope that makes sense, Nate.
所以整體而言,我會說,當你放眼全球,我覺得——如同我們在講稿中提到的——第一季相較第二季我感覺不錯,需求型態大致相同。但目前我無法真正給你第三季與第四季的走勢判斷,因為總體環境的因素,以及中國可能再度因 COVID 封控等疑慮。希望這樣說得通,Nate。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Yes, definitely. And maybe just a quick follow-up. -- were you, I guess, able to size kind of the headwind from the lockdowns in China? And with that -- in that market specifically, have you started to see those volumes recover as we're starting to see those lockdowns ease?
是的,完全理解。再追問一個——你們是否能量化中國封控帶來的逆風影響?另外,就該市場而言,隨著封控開始緩解,你們是否已經看到量能回升?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
For sure. I mean it's direct correlation there as soon as they let Shanghai open again, we saw it reflected in our order rates there. And look, we continue to feel good about China in a stable market. It's just the dramatic way that China continues to address COVID cases by major cities. This just creates a huge amount of uncertainty as when the next lockdown will be.
當然。我是說,兩者有直接的相關性;上海一重新開放,我們就看到當地訂單率反映出來。你看,我們在市場穩定的情況下,對中國仍然很有信心。只是中國持續以主要城市的方式來處理 COVID 個案,手段相當劇烈,這就造成很大的不確定性:下一次封控會在什麼時候發生。
Operator
Operator
The next question is from the line of Elizabeth Anderson with Evercore.
下一個問題來自 Evercore 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
One thing I was wondering if you could comment about -- I know in the sort of fourth quarter of last year, and into the first quarter, you did increase the sales hiring, sequentially and year-over-year. Could you sort of talk through sort of the impact of those salespeople? Where are they in the ramp process? And how do you -- should we think about their potential for contributing in the back half of the year?
我想請你們評論一件事——我知道在去年第四季到今年第一季,你們在銷售招募上,不論季比或年比都有增加。你們能否談談這些業務人員帶來的影響?他們目前在上手(ramp)流程的哪個階段?以及我們應該如何看待他們在下半年可能的貢獻?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
That's a good question, Elizabeth. Obviously, in our sales force -- being a direct sales force is really important to us in that way. And so the way we do this, obviously, as you indicated, we hire a lot of salespeople upfront. We have sales training programs too that help to initiate them as they come into the corporation.
這是個好問題,Elizabeth。顯然,對我們而言,銷售團隊——作為直銷團隊——在這方面非常重要。因此我們的做法是,如你所說,我們會在前期大量招募業務人員。我們也有銷售訓練計畫,協助他們進入公司後完成導入。
But I would tell you, depending on where you are around the globe, there is a 6-month and 9-month burn-in period before you really feel that they're up to speed. They understand the Invisalign system, the digital platform and those types of things. So I would say in some simpler kinds of situations geographically, it could be 6 months. But in general, it's 9 months or so before we have confidence that they're going to be really good on their feet as they talk to our doctors.
但我會告訴你,取決於你所在的全球區域,在你真正感受到他們完全上手之前,會有 6 個月到 9 個月的磨合期。他們需要理解 Invisalign 系統、數位平台以及這類事項。所以我會說,在某些地理上相對簡單的情況下,可能是 6 個月。但一般而言,大約 9 個月左右,我們才會有信心他們在與醫師溝通時能真正站穩腳步、表現出色。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Got it. That's helpful. And then 1 thing that depressed me in the quarter a little bit was about the tea number. I know that sometimes it's been off because of COVID in terms of seasonality, and it's not necessarily always the strongest quarter for teeth. But how are you thinking about that versus the economic sensitivity of adult cases and sort of how -- do you expect that to sort of trend in the sort of near term?
了解,這很有幫助。然後有一件事讓我在本季有點沮喪,是關於青少年(teen)數字。我知道有時因為 COVID 的關係,季節性會失真,而且這不一定總是青少年最強的季度。但你們如何看待這點,相對於成人病例對經濟的敏感度?以及你們是否預期這在短期內會如何走勢?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Keep in mind, we see a lot more concern from an adult standpoint, when you look year-over-year in the sense of our order growth in adults, I mean it's been affected Elizabeth, and there's a lot of data that we produce that will show you that. On the teen side, it's hard to pull a lot of the second quarter because it really starts in the third quarter. But I felt overall good about it, but again, not surprised because we've always felt that teens have a certain window of time from a treatment standpoint. And so it's not necessarily an emotional purchase in a way, it's usually planned for and anticipated. And what we saw between the second quarter and beginning of the third quarter, it really bears that out.
是的。請記住,從成人端來看,我們看到更多的擔憂;如果你看年對年、以成人訂單成長的角度來看,確實受到影響,Elizabeth,而且我們產出的很多數據都會顯示這一點。至於青少年端,第二季其實很難看出太多,因為青少年旺季真正是從第三季開始。但整體我感覺不錯,不過也不意外,因為我們一直認為青少年在治療上有一個特定的時間窗口。所以這不一定是一種情緒性消費,通常是事先規劃並預期的。而我們在第二季與第三季初看到的情況,也確實印證了這點。
Operator
Operator
Our next question is from the line of Jon Block with Stifel.
我們的下一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Great. I'll follow up on teen, maybe just to go there. I think worldwide teen was down year-over-year. And I believe, Joe, you mentioned that teen and APAC was up year-over-year, which sort of implies that North American teen was down maybe a decent amount. So anything to call out there? Why do we see that maybe specific to North America? And then more importantly, you did have some positive commentary around teen case packs, you talked about enrollment. So maybe just talk to us on how long it might take for the teen case pack program in North America to give that segment a shot in the arm and then your plans to roll that out internationally. I've got a follow-up.
很好。我想追問青少年,先從這裡開始。我認為全球青少年年對年是下滑的。而且我相信,Joe,你提到 APAC 的青少年年對年是成長的,這似乎意味著北美的青少年可能下滑得比較明顯。這裡有什麼需要特別指出的嗎?為什麼會在北美特別看到這種情況?更重要的是,你們對青少年 case packs 有一些正面評論,也談到註冊(enrollment)。所以請談談北美的青少年 case pack 計畫需要多久才能為該細分市場帶來提振,以及你們將其推向國際市場的計畫。我還有一個追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jon, on the teen side, remember, we kind of lost -- or we had a muted signal on the teen side. It needs to be very clear from quarter-to-quarter before COVID. If you remember last year, it was much more muted. This year, we're hoping to see a less muted cycle. And I think we're starting to feel that, Jon. So it's -- I don't think you can look too much between -- what we're doing between the first quarter and second quarter and pull a clear teen signal out of there.
Jon,在青少年端,請記得我們某種程度上失去了——或是說青少年端的訊號被弱化了。在 COVID 之前,它需要在季度之間非常清楚才看得出來。如果你記得去年,訊號就弱化得多。今年我們希望看到一個弱化程度較低的循環。我想我們開始感受到這點了,Jon。所以——我不認為你能從第一季到第二季之間我們所做的事情,抽出一個非常清晰的青少年訊號。
The other thing on teen too is there's always competitive concern with other clear aligner whatever. But basically, this is a wires and brackets competition with us. It's always been and continues to be that way. And in new products that we're launching these teen packs, we feel good about them. They've been -- as I mentioned in my script too, they've been received well. And it's been with the lower-end orthodontics from our standpoint that haven't done a lot of teen cases in the past. And that's a segment that we were fishing for to give them more confidence to be able to move in with teens.
另外,青少年端也一直存在來自其他隱形矯正器之類產品的競爭疑慮。但基本上,對我們而言,競爭一直、也仍然主要是來自傳統鋼絲與矯正器(wires and brackets)。而在我們推出的新產品——這些青少年套裝(teen packs)——我們感覺不錯。如同我在講稿中提到的,它們的市場反應很好。這主要發生在我們所說的較低端正畸市場,那些過去沒有做很多青少年病例的醫師。這正是我們想要觸及的族群,讓他們更有信心切入青少年。
So we're not declaring victory, but we feel we have a good product that's timed well. And we're not seeing the cycles in the teen marketplace as we're seeing in the adult marketplace. And obviously, Jon, as we get through the third quarter, we'll have a much better understanding of how we turn out that way. But I didn't pull anything out between the first and the second quarter that concerned me.
所以我們不會宣告勝利,但我們覺得我們有一個時機點很好的好產品。而且我們沒有在青少年市場看到像成人市場那樣的循環波動。當然,Jon,等我們走過第三季,我們會更清楚了解結果會如何。但我沒有從第一季到第二季之間看到任何讓我擔心的訊號。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Got it. Helpful. And then for my second one, let me try to maybe jam 2 in 1 and hopefully not make a mess of it. So just for us on the 3Q versus 2Q overall case volumes, China is reopened. China is a decent chunk of business for you guys. So if China snaps back, you talked about Shanghai, then maybe talk to us on why we wouldn't see you guys resume some sequential growth 3Q versus 2Q? I know there's many other markets.
了解,很有幫助。那第二個問題,我試著把兩個塞在一起,希望不要搞得太亂。就我們來看第三季相較第二季的整體病例量,中國已經重新開放,而中國對你們來說是相當大的一塊業務。所以如果中國快速回升,你也談到上海,那你能否談談為什麼我們不會看到你們在第三季相較第二季恢復一些季比成長?我知道還有很多其他市場。
And then maybe just to stick with China. I just love your thoughts on what's going on over there, maybe in terms of market share, your main competitor had some quasi numbers out recently. It looked like they were down mid-single digits in [cases] 1H22 year-over-year, which quite honestly, I actually thought that was a good number considering the environment. So I would love your thoughts on just China and your ability to hold share on what's going on from a market share perspective?
然後也許就聚焦在中國。我很想聽聽你對那邊正在發生的事情的看法,可能從市占率的角度來看。你們的主要競爭對手最近公布了一些類似的數字,看起來他們在[病例] 22年上半年(1H22)同比下降了中個位數,老實說,考量到當前環境,我其實覺得那是個不錯的數字。所以我很想聽聽你對中國的看法,以及從市占率角度,你們在那邊維持份額的能力如何?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I'll start with the China and kind of move backwards, Jon. And I'll get John involved here, too. But from the China side, obviously, we saw what you published there, whatever, but I looked at a Angelalign numbers, and it's basically same thing we experienced. I mean, we experienced a shutdown of Shanghai, slowdowns in some other regions, and there was nothing in those numbers that really surprised me. As I look at China, our ability to compete there. I feel great about it. And again, our investments we've made there in treatment planning and manufacturing. We've only added to that. The efficiency of those organizations have done well.
是的。Jon,我先從中國談起,然後再往回說。我也會讓John一起加入。不過就中國這邊來看,顯然我們看到了你們那邊發布的內容等等,但我看了Angelalign的數字,基本上和我們的經驗是一樣的。我的意思是,我們經歷了上海封控、其他一些地區放緩,而那些數字裡沒有什麼真的讓我意外的。當我看中國市場、我們在那裡的競爭能力時,我感覺非常好。而且再說一次,我們在那裡於治療方案規劃與製造方面所做的投資,我們只是在此基礎上持續加碼。那些組織的效率表現得很好。
Our product is great for that marketplace, and some of the most difficult cases that we encounter exist there, too. So I feel good about our ability to compete in that market against Angel or anyone else who's there. We just need a stable marketplace that we can operate in, and it hasn't been stable for -- goodness what -- it's been, what, almost 2 years.
我們的產品非常適合那個市場,而且我們遇到的一些最困難的病例也存在於那裡。所以我對我們在那個市場與Angel或任何其他在那裡的競爭者競爭的能力感到樂觀。我們只是需要一個我們能夠運作的穩定市場,但它一直不穩定——天啊,這——已經,什麼,快2年了。
And I mean I just read this morning, the Wuhan's looking at the close down. So I mean, Jon, there's a lot of variability there, a concern with COVID and shutdowns, particularly in the second half of this year in China, but I continue to be concerned about that can disrupt the marketplace. But if that stays clear, we're going to have China in the second half that we can operate from. To answer your question, I feel good about our competitive position there, our ability to compete against with anyone.
而且我的意思是,我今天早上才看到,武漢看起來又在考慮封控。所以,Jon,那邊變數很多,對COVID與封控的擔憂,特別是在今年下半年中國,仍然存在;我也持續擔心這會擾亂市場。但如果這些狀況能保持不發生,我們下半年就能在中國正常運作。回答你的問題,我對我們在那裡的競爭地位、以及與任何人競爭的能力都很有信心。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And we should see some of the sequential history that we normally see in our business. It goes to what Joe said that there's just some unforeseen variables that are still there. If there is a shutdown in China, that will impact our numbers. If there's no shutdown, we should see sequential improvement. And then you have some of the other macro economics that we've talked about in terms of potential recession or other things that people are concerned about, that affects their decisions on whether they go into treatment. But we're watching closely to see how sequentially things are behaving and making investments appropriate based on what we see.
而且我們應該會看到一些我們業務中通常會出現的環比走勢。這也呼應Joe所說的,仍然有一些不可預見的變數存在。如果中國出現封控,會影響我們的數字;如果沒有封控,我們應該會看到環比改善。然後還有一些我們談過的其他宏觀經濟因素,例如潛在衰退或其他人們擔心的事情,這會影響他們是否開始治療的決策。但我們會密切觀察環比表現如何,並根據我們看到的情況做出適當投資。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
And Jon, sorry, just staying back to your second question...
Jon,抱歉,回到你第二個問題……
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Sorry. if I can just jump in...
抱歉,如果我可以插一句……
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Go ahead, Jon.
你說吧,Jon。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Sorry, Joe. I was just going to say, John and Joe, maybe to follow up on that lasts comment just for clarity purposes because I think it's an important one. Are you guys saying sort of as you sit here today, who the heck knows what's going on with Wuhan or I don't know, something worse incrementally with the economy. But as we sit here today in late July, you're expecting the resumption of sequential growth off the 2Q number, this evening?
抱歉,Joe。我只是想說,John和Joe,也許針對你剛才最後那個評論再追問一下,為了釐清,因為我覺得那點很重要。你們的意思是,站在今天這個時間點,誰知道武漢會怎樣,或是經濟還會不會更糟。但就我們現在在7月下旬的情況來看,你們預期今晚所談的,會在第二季(2Q)數字的基礎上恢復環比成長嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I'd say, Jon, expecting anything in this market might be a sign of a low IQ. When you look at what's going on in China, I'm not going to sit here and tell you I expect a stable market in the second half based on their COVID policies. So I hope -- from the United States standpoint, there's a lot going on, trying to explain to the teen market overall outside of China, I feel is the most stable market we have, and the one that we're ready to compete with, and we're moving into seasonality, what really makes a difference.
嗯,Jon,我會說,在這種市場裡「期待」任何事情,可能是低智商的表現。看看中國正在發生的事,基於他們的COVID政策,我不會坐在這裡告訴你我預期下半年會是一個穩定的市場。所以我希望——從美國的角度來看,外部有很多事情在發生;如果要解釋青少年市場,整體而言,在中國以外,我覺得那是我們最穩定的市場,也是我們準備好去競爭的市場,而且我們正進入季節性,這才是真正會帶來差異的因素。
We have -- we're positioned well with products. But as you know, Jon, as well as anybody, that's always been a wires and brackets marketplace. We've been taking share 1.5 points, 2 points a year. We're hoping some moves we make can make that better, but we'll know a lot more when the third quarter is over in that sense.
我們——在產品方面的布局很好。但如你所知,Jon,跟任何人一樣清楚,那一直都是一個金屬矯正器(wires and brackets)的市場。我們每年一直在拿下1.5個點、2個點的份額。我們希望我們做的一些動作能讓這更好,但在這方面,等第三季結束後我們會知道更多。
Operator
Operator
Our next question comes from the line of Jeff Johnson with Baird.
我們的下一個問題來自Baird的Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Joe, so I just wanted to talk maybe on the doctor shipped to that number this quarter. It's trended down each of the last couple of quarters. this quarter in the Americas, it did trend back up just a touch. What are your views on what that means? Is that a -- market stabilized a little bit? Is that maybe the competitive positioning is stabilizing a little bit? Just how do you view that number in the Americas? And is there room left in the Americas for that number over the next couple of years to keep moving higher? Are you kind of at a point where you've saturated kind of the Americas market with a number of doctors who are going to be performing in these cases?
Joe,我想談談本季「出貨至醫師(doctor shipped to)」這個數字。它在過去幾季每一季都在下滑;而本季在美洲地區,這個數字又小幅回升了一點。你怎麼看這代表什麼?這是否意味著——市場稍微穩定了一些?或是競爭態勢稍微穩定了一些?你如何看待美洲地區這個數字?另外,未來幾年在美洲,這個數字還有空間繼續走高嗎?還是你們已經到了某個程度,基本上已經把美洲市場中會做這些病例的醫師數量「滲透」得差不多了?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Just to answer your last part of your question first, Jeff. No, we have a lot of room to grow in the Americas, too, in United States, Canada, but also you have to throw in Latin America and Brazil in that. There's a lot of growth, John and I have ported over these numbers a lot.
Jeff,我先回答你問題的最後一部分。不,我們在美洲也還有很大的成長空間,包括美國、加拿大,但也要把拉丁美洲和巴西算進去。成長空間很大,John和我也多次把這些數字拿出來說明。
What happens -- I feel, if you back these numbers up before really the big surge in orders that we had before, we can draw a line through these things. It doesn't upset us. You have to split orthos and GPs very clearly. Remember, you have some GPs that do like 3 cases a year. As things kind of slow down, they'll be out of the circulation for a while and then they order another and whatever. And these numbers will go up 81,000, 82,000, we'll see them go up and down. But don't look at this in any way as that we're saturated in this marketplace, both from an orthodontic standpoint and a GP standpoint.
我覺得會發生的是——如果你把這些數字往回看,回到我們之前那波訂單大幅激增之前,其實可以在這些數字上畫出一條趨勢線。這不會讓我們不安。你必須非常清楚地把矯正專科(orthos)和一般牙醫(GPs)分開。記住,有些GP一年只做大概3個病例。當整體放緩時,他們可能會暫時不在循環裡,過一陣子又下單一個之類的。這些數字會到81,000、82,000,會上下波動。但不要用任何方式把這解讀為我們在這個市場已經飽和,無論是從矯正專科或GP的角度。
Jeff, the other thing too, I think, that people forget from an orthodontic standpoint is that our orthodontists who do teens. These are orthodontists that are really committed to Invisalign for the most part, and they do a lot of teens. But we still have a significant amount of orthodontists who do Invisalign almost exclusively for adults. And so you'll see that whole piece from a utilization standpoint as we increase our team penetration, you should see the utilization rates there improve.
Jeff,另外一點,我想大家從矯正專科的角度常常會忘記的是:我們那些做青少年病例的矯正醫師,基本上大多對Invisalign非常投入,而且他們做很多青少年病例。但我們仍然有相當多的矯正醫師幾乎只用Invisalign來做成人病例。所以從使用率(utilization)的角度來看,當我們提高青少年滲透率時,你應該會看到那一塊的使用率提升。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Yes, that's helpful. And then maybe kind of a follow-up on all that a 2-parter, just the international number again, kind of did tick down a little bit that number of doctors shipped to internationally. One, I would assume you think there's a lot more room even there to saturate that market over the next few years, that would seem to make sense to me anyway.
是的,這很有幫助。然後也許再追問一下,算是兩個部分:國際市場的那個數字——國際「出貨至醫師」的醫師數量——又小幅下降了一點。第一,我想你應該也認為,即使在那邊,未來幾年要把市場滲透到更高程度仍然有很大空間,至少我覺得這樣看起來是合理的。
But is there any way to look at what that number did in China? And was there sequential decline largely driven by the shutdowns in China? Or ex China, would that number have been up? And then I was a little surprised to hear cases down, I think you said in U.K. year-over-year. Is that just a tough comp? Or what's going on in the U.K.? I think we are all aware of China pressures in early, Japan pressures or early quarter Japan pressures, but U.K. caught me off guard a little bit there.
但有沒有辦法看出那個數字在中國的表現?以及這次的環比下滑是否主要是由中國封控所驅動?或者如果排除中國,那個數字其實會是上升的?另外,我有點意外聽到你說英國(U.K.)的病例數同比下降。我想你說的是同比吧。那只是因為比較基期太高嗎?還是英國發生了什麼事?我想我們都知道中國在年初的壓力、日本在季度初的壓力,但英國這點有點讓我措手不及。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I'll answer the U.K. piece first. The U.K. was outstanding for us last year. Remember, Europe grew 300% for us last year, Jeff, right? The U.K. led that. So I'm sure that U.K. number is higher than what that aggregate number is. And so what you're seeing is kind of adult kind of a retrenchment in the U.K. from an order standpoint, but not an indication of a utilization issue that I'd say, across the doctor base that we have in the U.K. John, I don't know...
我先回答英國的部分。英國去年對我們來說表現非常出色。記得嗎,Jeff,歐洲去年對我們成長了300%,對吧?英國是帶頭的。所以我確定英國那個數字其實比你看到的那個匯總數字要高。你現在看到的是,從下單角度來看,英國的成人市場有點回撤(retrenchment),但這並不代表我會說在英國我們的醫師基礎整體存在使用率問題。John,我不知道……
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And just on the China piece or the APAC piece for international. So that was certainly an impact in terms of the lockdowns, and doctors just not being able to transact and therefore, don't have shipped to. So the international side of the doctor shipped to was certainly impacted by COVID. We won't break it out by kind of the subregions. But that was an impact that -- look, as those offices open up, as those lockdowns are minimized, we would expect that to increase from a shipped to standpoint.
再談中國或亞太(APAC)在國際市場的部分。封控確實造成了影響,醫師無法進行交易,因此也就沒有「出貨至」的數字。所以國際端的「出貨至醫師」確實受到COVID影響。我們不會按子區域去拆分披露。但那確實是一個影響——你看,當那些診所重新開放、封控減少時,我們預期從「出貨至」的角度,這個數字會上升。
Operator
Operator
Our next question is from the line of Justin Lin with William Blair.
我們的下一個問題來自 William Blair 的 Justin Lin。
Justin Lin - Research Analyst
Justin Lin - Research Analyst
Can you just touch on your sales and marketing spending strategy a little bit in the short term and longer term? I guess, when can you sort of decide to flip the switch?
您能否談談短期與長期的銷售與行銷支出策略?我想問的是,您大概何時會決定「切換開關」?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
You mean flip the switch as far as up or down?
您是指就上調或下調而言的「切換開關」嗎?
Justin Lin - Research Analyst
Justin Lin - Research Analyst
Yes. Yes.
是的。是的。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I mean, obviously, obviously, we saw our adults dramatically decreased. And so the return on investment in some specific geographies. John and I take a look at it, and we don't eliminate it, but we reduce it in accordance with what we think the demand pattern is. And we spread it around into other countries that we feel we can get a higher return on. And we're just basically sizing our advertising to what we think the demand patterns are around the business in different areas.
是的。我的意思是,很明顯、很明顯,我們看到成人需求大幅下降。因此在某些特定地區的投資報酬率方面,我和 John 會一起檢視;我們不會把它完全取消,但會依照我們認為的需求型態來降低投入。同時,我們也會把資源分配到其他我們認為能取得更高報酬的國家。基本上,我們是在依據不同地區業務的需求型態,來調整我們的廣告規模。
And so I wouldn't look at this as any way that we'll continue to advertise aggressively and promote our brand and to drive value in our change to bring customers to our doctor base, but we can be responsible to we can advertise at the rate that we did last year when we were growing at over 100% in a lot of these regions, we have to modify it somewhat in order to address that demand pattern.
因此我不會把這看成是我們會停止積極投放廣告;我們仍會持續做品牌推廣,並透過我們的變革來創造價值、把客戶帶到我們的醫師基礎(doctor base)。但我們也必須負責任——我們不可能用去年那種投放速度來做廣告,因為去年在許多地區的成長超過 100%;我們必須做一些調整,以因應那樣的需求型態。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And we adjust into the market. So keep the overall brand awareness, keep that averages. Remember, still sudden spending even as we rightsize things, hundreds of millions of dollars in marketing and media to be able to go to market, drive that awareness. But then in certain markets, if there's COVID or if there's economic concerns and so on, we're adjusting things to make sure that we rightsize and continue to make sure that we make the right trade-off between how we're investing in go-to-market, and continue to invest in the rest of the business like R&D and operations.
而且我們會隨市場調整。所以要維持整體品牌知名度,維持那些平均水準。請記得,即使我們在重新調整規模,我們仍然投入大量支出——數億美元的行銷與媒體費用——以便推向市場、提升知名度。但在某些市場,如果有 COVID 或經濟疑慮等等,我們就會調整,確保規模適當,並持續在「市場推廣(go-to-market)的投資」與「對研發與營運等其他業務的持續投資」之間做出正確取捨。
Justin Lin - Research Analyst
Justin Lin - Research Analyst
Got it. That's very helpful. And I guess just pivoting to a more sort of higher-level question. Any update on commercial operations in sort of your emerging markets like Brazil, India, Africa, what would you say current penetration levels are over there? And I guess, realistically, how much revenue can you capture from those regions in the next, let's say, 5 to 10 years?
了解。這很有幫助。我想再轉到一個更高層次的問題:在巴西、印度、非洲等新興市場的商業營運方面,有沒有最新進展?您會怎麼描述目前在那邊的滲透率?以及更務實地說,在未來 5 到 10 年,您們能從那些地區取得多少營收?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
And the region that you mentioned were really underpenetrated, huge opportunity. I mean we've seen great progress in Brazil. We're seeing good progress in India. Reported in -- I mean, it's -- when we talk about those 500 million patients, they're out there. And the way to get them is we do -- we put salespeople in place. We put the right kind of capability on the ground. This is a direct sales force that you have to have in order to sell our product line.
您提到的那些地區確實滲透率很低,機會非常大。我們在巴西看到很好的進展,在印度也看到不錯的進展。至於——我的意思是——當我們談到那 5 億名患者時,他們就在那裡。而要觸及他們的方法是:我們會——我們會配置業務人員,建立正確的在地能力。這是一支你必須具備的直銷團隊,才能銷售我們的產品線。
But to answer your specific question, the penetration rates aren't even close. And that's -- again, you can see that in our script, that's how we remain so confident that in a stable environment, we'll continue to perform really well.
但就您具體的問題而言,目前的滲透率還差得很遠。也正因如此——再說一次,您可以從我們的處方量(script)中看到——這也是為什麼我們仍然非常有信心:在一個穩定的環境下,我們會持續表現得很好。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And we're built as a company to really expand into those markets. We've got that global footprint for manufacturing now in all 3 geographies. We've got treatment planning. We've got that go-to-market sales force -- direct sales force with great products. So we're built in all those markets. We like the dynamics of these markets where you have a growing middle class, big population. You've got people who want to straighten their teeth, and we've got a great way for them to get to that. So all the markets you described as well as many others, those are where we think of some of the investments because it's a great return on those investments.
而且我們公司的建置就是為了真正擴張到那些市場。我們現在在三大地理區域都已建立製造的全球布局;我們有治療規劃;我們有市場推廣的銷售團隊——直銷團隊——以及很棒的產品。所以我們在所有那些市場都已具備條件。我們喜歡這些市場的動態:中產階級成長、人口龐大;人們想把牙齒矯正整齊,而我們提供了一個很好的方式讓他們做到。因此,您描述的所有市場以及其他許多市場,都是我們考慮投入的一些方向,因為這些投資的報酬很高。
Operator
Operator
Our next question is from the line of Jason Bednar with Piper Sandler.
我們的下一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Yes. So Joe, I'll go big picture here in the U.S. market, and maybe go back to clarifying point on Jon Block's question earlier. I mean on one hand, demand in the category broadly just did seem to show some signs of moderation in the second half of last year. relation to a bit of a leading indicator in other parts of high end dental on the help of the average consumer.
是的。Joe,我先從美國市場的大方向來問,並且可能回到先前 Jon Block 問題中的一個釐清點。一方面,這個品類的整體需求在去年下半年似乎確實出現一些放緩跡象,這可能與高端牙科其他領域的一些領先指標有關,也反映一般消費者的狀況。
I mean this needs are going to be coming into some easier absolute comparisons as we head into the back half of this year, which I don't know, maybe helps reverse this downtrend in Invisalign case growth. But I guess we're also in the early days of what still could be some more pain coming for the consumer. So I guess what dominates in your opinion? Do the easier comps dominate? Or does it more challenge on consumer dominate? And again, just thinking about the domestic market here and ignoring again some of that China and predictability that's out there.
我的意思是,隨著我們進入今年下半年,這些需求在絕對值比較上會變得更容易一些;我不知道這是否有助於扭轉 Invisalign 病例成長的下滑趨勢。但我想我們也仍處於一個可能還會有更多消費者壓力的早期階段。所以您認為哪個因素更主導?是更容易的比較基期更主導?還是消費者面臨的挑戰更主導?同樣地,這裡只談國內市場,先不考慮中國以及那邊的可預測性等因素。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I'll let John take a shot at this, too. But I would say, I mean, obviously, you talk about easier comps. I mean when you're comping against 300% growth, like we just talked about, it's one of the tougher comps on a large number I've had in my business career. And so obviously, when you get some light on that line, it helps somewhat. But consumer confidence, I'd say, outside of the COVID, the way I'd look at the business again is COVID affected Asia in a big way.
是的。我也讓 John 一起回答。但我會說,您提到比較基期變容易——當你是在跟 300% 的成長做比較(就像我們剛剛談到的),以我職涯來看,這是我遇過在大數基礎上最難的比較之一。所以當那條線稍微變輕鬆一些,確實會有些幫助。但我會說,除了 COVID 之外,消費者信心才是我們主要看的因素。再從業務角度來看,COVID 對亞洲的影響很大。
We had some COVID staffing issues or whatever, but predominantly in the West, it's consumer confidence that we look at. And so those consumer confidence numbers start to equalize, start to get better. Some of the ones we look in Europe are all-time lows. I feel that means a lot. It means that means more to meet in those comparisons years from here. We would report more confidence in consumers in a trend where in that kind of environment, we think we see the adult cases resume at a pace that we'd be equal to our long-term growth rate.
我們也有一些 COVID 的人力配置問題之類的,但在西方市場主要看的還是消費者信心。因此當消費者信心數據開始趨於平穩、開始改善——我們看到歐洲的一些數據是歷史新低——我覺得那代表很多意義。那在未來幾年的比較中會更重要。我們會在消費者信心呈現改善趨勢時更有信心;在那樣的環境下,我們認為成人病例會以接近我們長期成長率的速度恢復。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Yes. It's consumer confidence overall, and in certain cases (inaudible)
是的。整體而言是消費者信心,而在某些情況下(聽不清)。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
I guess just real quick, I guess I would -- Yes. I guess I was just focusing more on the U.S. market. And I totally understand Europe and China and APAC and all the different dynamics there. But just in within the U.S. market, I mean, the comps do get easier, absolute comps -- they did tick down starting in the second half of last year. So just that would be where I'd be focusing the question here, sorry to interrupt.
我想很快補充一下——是的。我想我剛剛更聚焦在美國市場。我完全理解歐洲、中國、亞太等各地不同的動態。但就美國市場內部而言,比較基期確實會變得更容易,絕對值的比較——從去年下半年開始就已經下滑。所以我想把問題聚焦在這裡,抱歉打斷。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. No, Jason, that's okay. I look at the United States too is -- I just give you consumer confidence more than anything. Not just saying that there's no big variant issue or something that happens with COVID. We're all kind of have PTSD in that sense and what we experienced over the last 2 years. But yes, I like the comparison year-over-year. That's going to be helpful. But those consumer confidence numbers, whether I'm talking about Europe or I'm talking about the States, those are the ones that we stay glued to that we think are a really good indicator in the sense of our market, and that adult market that we appeal to, both in the GP segment in the adult market and the orthodontic segment, too. John, anything?
是的。不會,Jason,沒關係。我看美國也是——我主要還是看消費者信心,勝過其他因素。當然前提是沒有出現什麼重大變異株問題或 COVID 又發生什麼事;在這方面我們多少都有 PTSD,因為過去兩年的經歷。但沒錯,我喜歡年對年的比較,這會有幫助。不過那些消費者信心數據,不論我談的是歐洲或美國,都是我們緊盯的指標;就我們的市場、以及我們所吸引的成人市場而言——不管是在一般牙科(GP)端的成人市場,或是矯正科端——我們認為那是非常好的指標。John,你有要補充嗎?
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And the piece that I would add to the U.S. is just that as we get into teen season now as we go from Q2 to Q3. Teens will be important to see. We've got great products. We've got great go-to-market opportunities to be able to grow in those markets and get more market share. When we think of teens everywhere in the world, it's single digit and even in the U.S. So we look at growth opportunities that will be teens, maybe a little bit less of more resistant to maybe some of that consumer concerns that they have. Consumer concerns certainly show up on the adult side, but we think teams can help offset that just a bit because it's less discretionary.
我想對美國補充的一點是:當我們進入青少年旺季、從第二季走到第三季時,青少年會是重要觀察點。我們有很棒的產品,也有很好的市場推廣機會,能在那些市場成長並取得更多市占。當我們看全球各地的青少年滲透率時,都是個位數,即使在美國也是如此。所以我們認為成長機會會來自青少年;相較之下,他們可能對某些消費者疑慮的抗性更高一些。消費者疑慮確實會在成人端更明顯,但我們認為青少年可以在一定程度上抵消一些影響,因為這比較不屬於可自由支配的消費。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Okay. That's helpful. And maybe just a quick follow-up here. A lot of questions out there right now from investors on the decremental margin impact for the business with volumes and revenue doing what it's doing here. You added a lot of head count. It's significantly expanded branding and advertising efforts during the pandemic really helped to widen the competitive moat, so really impressive. It sounds like some of that marketing though has been recalibrated here. Are there further resets that -- with the OpEx structure that might be necessary in this environment? And I guess, what's the trigger for you to decide that a further rightsizing is necessary?
好的,這很有幫助。我再快速追問一下:目前投資人有很多問題在問,關於在目前量與營收表現下,業務的遞減邊際(decremental margin)影響。你們增加了很多人力,並在疫情期間大幅擴大品牌與廣告投入,確實有助於擴大競爭護城河,這非常令人印象深刻。聽起來其中一部分行銷已經在這裡重新校準。在這樣的環境下,營業費用(OpEx)結構是否還需要進一步重設?以及你們判斷需要進一步調整規模(rightsizing)的觸發點是什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I mean rightsizing, when I hear words like that, it means that we've gone to the layoffs, so we haven't laid anything off. Remember, we -- any one off in that sense. We normally hire to a 20% to 30% growth rate. And so -- and we -- our OpEx spend is in that range, too. So obviously, we didn't -- we couldn't hire in that range. And so if you call that a cutback, it's a cutback from our normal OpEx.
我的意思是,所謂的「規模調整」(rightsizing),當我聽到這種字眼時,通常就代表我們已經進行裁員了,但我們並沒有裁員。請記得,我們——在那個意義上——沒有做任何一次性的裁撤。我們通常是以 20% 到 30% 的成長率來招募人力。因此——而且我們——我們的營運費用(OpEx)支出也大致落在那個區間。所以很明顯,我們沒有——我們無法以那個幅度去招募。若你把這稱為縮減,那它是相對於我們正常 OpEx 水準的縮減。
What we do is we normally balance OpEx to revenue at about a 50% range, and there's a lot of variables in that line from an OpEx standpoint that we can go about. Remember, our most important areas that we want to make sure we take care of is our commercial team, our engineering effort and also our marketing. We know those are really key. And we focus on those, and we balance the business around them. John, anything you want to add?
我們通常會把 OpEx 與營收的比例平衡在大約 50% 的區間,而在 OpEx 這條線上有很多變數是我們可以調整的。請記得,我們最重要、一定要確保照顧到的領域是商務團隊、工程研發投入,以及行銷。我們知道這些非常關鍵。我們會聚焦在這些面向,並以此來平衡整體業務。John,你有什麼要補充的嗎?
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
It's a balance, both short and long term. So as we balance out our plans, we look to -- the growth opportunities we have, we want to make sure we continue to invest in those growth opportunities. But then obviously, we have to be mindful of the current conditions that we're in, and we'll adjust as needed to still maximize the return on investments that we're making.
這是一種平衡,兼顧短期與長期。因此在我們平衡規劃時,我們會看——我們擁有的成長機會,並確保持續投資於這些成長機會。但同時,顯然我們也必須留意目前所處的環境,並在需要時調整,以便仍能最大化我們所做投資的報酬。
Operator
Operator
Our next question is from the line of Erin Wright with Morgan Stanley.
下一個問題來自 Morgan Stanley 的 Erin Wright。
Erin Elizabeth Wilson Wright - Equity Analyst
Erin Elizabeth Wilson Wright - Equity Analyst
Great. And I wanted to ask another Americas teen question here. But just given the seasonality and given this is an area where you should have some better visibility. I just want to clarify, does this mean you're going to see a meaningful sequential pickup in the coming quarter? Or why would that not happen for you? And just given that should be an area more under your control here.
好的。我想再問一個關於美洲青少年(teen)的問題。不過考量到季節性,而且這應該是你們能見度較高的領域,我想確認一下:這是否代表你們在接下來一季會看到顯著的季比回升?或者為什麼你們不會出現那樣的情況?畢竟這應該是更在你們掌控之下的領域。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Our normal growth pattern between the second quarter and the third quarter is flat to down 1 percentage point or so. John can confirm that. So the second quarter to third quarter is a big teen season, but there's other parts of our portfolio that kind of balance out with that. It's not traditionally a jump from second to third quarter. But again, we're focused on teens because we feel teens have a lot less elasticity than what adults have right now based on the consumer confidence level.
我們在第二季到第三季之間的正常成長型態是持平到下滑約 1 個百分點左右。John 可以確認一下。所以第二季到第三季確實是青少年旺季,但我們產品組合中還有其他部分會在某種程度上相互平衡。傳統上,從第二季到第三季並不會出現跳升。不過,我們之所以聚焦青少年,是因為基於目前消費者信心的水準,我們認為青少年需求的彈性比成人小得多。
So I just -- but I'd just caution you here. Remember, this is a wires and brackets play. It's something that's systemic that we have worked on for years. We have many new products like Invisalign First, Mandibular Advancement and several new teen products that help us with this. The new teen packs help also. We think we're well positioned, but we have to get into the quarter and be able to assess how well that market is actually holding up. John, anything...
所以我只是——但我想在這裡提醒你。請記得,這是一個「鋼絲與托槽」(wires and brackets)的競爭局面。這是我們多年來一直在處理的系統性議題。我們有許多新產品,例如 Invisalign First、Mandibular Advancement(下顎前移)以及數個新的青少年產品,這些都能幫助我們。新的青少年套裝(teen packs)也有幫助。我們認為我們的布局很到位,但我們必須進入該季度後,才能評估那個市場實際的支撐度如何。John,還有什麼……
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
But specifically in the U.S., U.S. teen, we should see sequential improvement as we get into teen season, going from Q2 to Q3, notwithstanding any occurrences that happened from an economic standpoint, but the expectation is given our products, given the opportunity, given the utilization that we have, we should be able to see growth. Now with that, anything else that gets in our way.
但就美國而言,美國青少年市場,隨著進入青少年旺季,從 Q2 到 Q3 我們應該會看到季比改善;當然這不包含任何從經濟面發生的事件,但在我們的預期中,考量到我們的產品、機會以及我們的使用率,我們應該能看到成長。當然,若有其他因素阻礙我們,那就另當別論。
Erin Elizabeth Wilson Wright - Equity Analyst
Erin Elizabeth Wilson Wright - Equity Analyst
Okay. And then ASPs for the balance of the year, how should we be thinking about that and the FX impact?
了解。那今年剩餘期間的 ASP(平均售價),我們應該怎麼看?以及匯率(FX)的影響呢?
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Erin, FX, obviously, Q1 to Q2 was a big impact in FX. We see it in the numbers from revenue all the way down to our EPS. I would think of -- it's tough to forecast where FX is going to go. Certainly, dollar has strengthened. I think you kind of take the numbers that they're at now and kind of play that forward for the rest of the year is how we look at that. I think from an overall ASP standpoint, there's always going to be puts and takes.
Erin,匯率方面,顯然從 Q1 到 Q2 的匯率影響很大。我們從營收一路到 EPS 都看得到它反映在數字上。我會這樣看——匯率走勢很難預測。美元確實走強了。我認為你可以用目前的匯率水準,並把它大致往後推算到今年剩餘期間,這也是我們的看法。至於整體 ASP,一直都會有利多與利空的拉鋸。
So we're not doing anything different from a discounting standpoint, how we're going to market and so on. You might have some mix effects that come through. But I take the FX rates kind of as they are now, project those forward and then ASP should be too much different than what you see now notwithstanding any FX.
所以我們在折扣策略、上市方式等方面並沒有做任何不同。你可能會看到一些產品組合(mix)效應的影響。但我會把匯率大致以目前水準為基礎往後推估,而 ASP 應該不會和你現在看到的差太多——當然要扣除任何匯率因素的影響。
Operator
Operator
The next question is from the line of Brandon Couillard with Jefferies.
下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
John, a quick follow-up on that FX question. I appreciate all the details in the deck. It is very, very helpful. Just curious, what is the estimated impact of currency on the operating margin for the year now in the ballpark?
John,針對剛才那個匯率問題我想快速追問一下。我很感謝簡報裡的所有細節,真的非常、非常有幫助。想請教一下:以目前來看,匯率對今年營業利益率(operating margin)的影響估計大概是多少?大概的區間即可。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Well, ballpark, I would look at that is about 1 point -- maybe just over 1 point of impact. We saw that 1.1 point impact from Q1 to Q2 in op margin. I would kind of look at the full year and about the same.
嗯,如果用大概的估算,我會看作大約 1 個百分點——可能略高於 1 個百分點的影響。我們看到從 Q1 到 Q2 的營業利益率受到 1.1 個百分點的影響。我會把全年大致也看成差不多的幅度。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
And then Joe, on the scanner business, any color between the North American segment and international in terms of growth rate, how would you sort of characterize the capital spending environment in those 2 regions, specifically?
接著 Joe,關於掃描器(scanner)業務,在北美與國際市場之間的成長率有什麼差異可以分享嗎?你會如何描述這兩個地區的資本支出環境,特別是?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I'll start with -- I mean, obviously, we had trouble selling scanners in China because China shut down. And China is one of our bigger markets, it's between China and Japan and Asia. So I didn't look at that so much as and overall market problem, I looked at that as more of a COVID problem. And so hopeful of, as I mentioned before, if that COVID stays clear, that will write itself.
是的。我先從——我的意思是,很明顯我們在中國銷售掃描器遇到困難,因為中國封控了。而中國是我們較大的市場之一,亞洲主要在中國、日本等地。所以我不太把它視為整體市場的問題,我更把它視為 COVID 的問題。因此我希望,如我先前提到的,如果 COVID 能保持受控,這個問題會自行修復。
United States, just a good job by the team, strong demand there. 5D plus tends to be the really strong scanner out there. On the restorative side, dentists liking the NIRI, the near-infrared technology for caries detection and orthodontists continue like the exactness of how our workflows at all from an overall iTero standpoint. So I feel good about the Americas and what the performance was in that piece. And as I mentioned in my script, is 40% with a large installed base now, 40% is services, too, which is really helpful in that business overall.
美國方面,團隊做得很好,需求強勁。5D plus 往往是市場上非常強勢的掃描器。在修復(restorative)端,牙醫喜歡 NIRI,也就是用於齲齒偵測的近紅外線技術;而矯正醫師則持續喜歡我們在整體 iTero 工作流程上的精準度。所以我對美洲地區在這一塊的表現感到樂觀。而且如我在講稿中提到的,現在在這個業務中,因為安裝基礎已經很大,約 40% 來自服務(services),這對整體業務也非常有幫助。
And look, I feel good about -- again, our scanners in Europe compared to get some pretty big numbers again last year. So I wouldn't be blinded by the year-over-year number in that sense. But Europe has the added pressure right now from a Ukraine standpoint. It's just -- it wears on the consumer sentiment piece. I think it makes doctors a little more reluctant and -- but there's -- I feel good about our position in Europe from a scanner standpoint. And as the market hopefully starts to stabilize here, we'll see that business that we had return loans.
另外,我對——再說一次——我們在歐洲的掃描器業務也有信心,儘管去年基期數字相當大。所以不要被年對年數字所迷惑。但歐洲目前還承受來自烏克蘭局勢的額外壓力。這會——它會拖累消費者情緒。我認為也會讓醫師更為保守、更加猶豫。不過——就掃描器而言,我對我們在歐洲的定位仍然有信心。隨著市場希望能逐步穩定下來,我們會看到那塊業務回到我們原本的水準。
Operator
Operator
Our next question is from the line of Kevin Caliendo with UBS.
下一個問題來自 UBS 的 Kevin Caliendo。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
So just want to think about how -- or what it would take for you guys to feel comfortable with providing guidance again, or feeling comfortable that you can hit your longer-term targets rather than making progress towards it. Do we need to see consumer confidence go back above 99 or something like that? Or I mean, at the beginning of the year, you caveated and said, listen, if there's no more COVID outbreaks, we'd still be able to do this.
我想了解一下——你們需要看到什麼,才會覺得可以再次提供財測(guidance),或是覺得你們能達成長期目標,而不只是朝目標前進?我們需要看到消費者信心回到 99 以上之類的水準嗎?或者——我的意思是,在年初你們有加註條件並說,如果沒有更多的 COVID 爆發,你們仍然能做到。
What do you need to see before you can come to us and say, "hey, we're back on track or we think we can do this." So we feel comfortable. We're going to be able to grow at ex rate going forward, even be able to provide guidance for like a quarter going forward, even if it's not for the full year. What needs to happen, in your mind?
在你們能回來跟我們說「我們回到正軌了」或「我們認為我們能做到」之前,你們需要看到什麼?讓我們能有信心:你們未來能以某個成長率持續成長,甚至能提供例如往後一季的指引,即使不是全年。你心目中需要發生什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I'll turn it over to John. But first of all is, remember, we don't carry inventory in this business outside of scanners. So it's a real-time business. We don't have any inventory to reflect from or any -- very little business from a week-to-week standpoint. So I'll move it over to John, but keep that in mind that we kind of feel these trends early on both ends. As the economy picks up, we'll probably feel it first. And as it turns down, we feel it by just the nature of the business first.
我會把這題交給 John。不過首先,請記得,除了掃描器之外,我們這個業務不持有庫存。所以這是一個即時(real-time)的業務。我們沒有庫存可以用來緩衝或反映——而且從週到週的業務緩衝也非常少。所以我先交給 John,但請把這點放在心上:我們在兩端都會很早感受到這些趨勢。當經濟回升時,我們可能會最先感受到;而當經濟轉弱時,基於業務性質,我們也會最先感受到。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
It really comes down to, Kevin, more just having more predictability on a macro basis, understanding as we mentioned COVID and thinking that we're through it, then you have China lockdowns or some of the consumer sentiment and things that come up that are outside of our control. We feel very good about being able to control what we can control, making the right investments as we go to market or adding investments in R&D to better our products and so on, and drive that return.
Kevin,這真的更取決於在總體環境上能有更高的可預測性。就像我們提到的 COVID,我們以為已經走過去了,結果又出現中國封控,或是一些消費者情緒等、超出我們掌控的事情。我們對於能掌控的部分非常有信心:在上市策略上做正確的投資,或在研發(R&D)上加碼投資以改善產品等,並推動投資報酬。
And therefore, like I said, we can manage to that 20%. That's something that we can manage as we go through the quarter. It really comes down to having more predictability on a macro basis. And once we get confidence in that, and we work our way to that understanding -- look, the economies are going to do what they're going to do. They're going to go up or down. But if I have more predictability on the direction that they're going and how they're going to go, then we can give a good forecast.
因此,就像我說的,我們可以把它管理到 20%。這是我們在整個季度推進過程中可以管理的事情。歸根結底在於在宏觀層面有更高的可預測性。一旦我們對此建立信心,並逐步形成這樣的理解——你看,經濟體該怎麼走就會怎麼走,可能上行也可能下行。但如果我對它們前進的方向以及將如何演變有更高的可預測性,那麼我們就能給出一個好的預測。
Operator
Operator
Our next question is from the line of Michael Ryskin with Bank of America.
我們的下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
I have kind of a follow-up to one of the earlier ones, and some that Kevin just asked sort of on the moving pieces going forward. I mean we spent a lot of time talking about China lockdowns and the impact that had, and there was some discussion on consumer confidence as well. But it was sort of brought up in the sense of, well, what happens when things improve.
我算是對前面某個問題做個追問,也呼應 Kevin 剛才問到的、關於未來各項變動因素的問題。我的意思是,我們花了很多時間談中國封控及其帶來的影響,也討論了一些消費者信心。但當時的語境有點像是:好吧,那如果情況改善會怎樣。
I hate to be the pessimist here, but can we talk about the other side of things as inflation is 1 thing and consumer sentiment and consumer confidence is another thing. But recessionary impact, if unemployment goes higher, if job losses start to accelerate, there is a scenario where things are -- should get worse for the next couple of quarters before they get better.
我不想在這裡當悲觀的人,但我們能否談談另一面:通膨是一回事,消費者情緒與消費者信心又是另一回事。但如果出現衰退影響、失業率上升、裁員開始加速,就存在一種情境:未來幾個季度情況——可能會在好轉之前先變得更糟。
So can you talk through sort of how you view the likelihood of that happening, the impact you think it will have on the business? And also sort of what's your response going to be, what's the game plan? You talked a little bit about controlling costs in the quarter already. What would be the other levers you would pull if things for the consumer in the Americas and in Europe get materially worse over the next 3 to 6 to 9 months?
所以你們能否談談你們如何看待這種情況發生的可能性、以及你們認為它會對業務造成的影響?另外,你們的應對會是什麼、作戰計畫是什麼?你們已經談到本季度在控管成本方面做了一些事。如果未來 3 到 6 到 9 個月,美洲與歐洲的消費者狀況實質性惡化,你們還會拉動哪些其他槓桿?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
It's Joe. Look, I think you've seen that -- I feel we've been responsible in the sense of adjusting the business to a lower demand signal than the business is used to having. I think you saw us respond the same way when COVID hit in March of 2020, and how we ran the business. If it gets worse, and it could get worse is the way -- I mean from the standpoint of whatever happens from an economic standpoint.
我是 Joe。你看,我認為你已經看到——我覺得我們一直很負責任,因為我們在把業務調整到一個比過去習慣的需求訊號更低的水準。我想你也看到我們在 2020 年 3 月 COVID 爆發時以同樣方式做出反應,以及我們當時如何經營業務。如果情況變得更糟——而它確實可能變得更糟——我的意思是,從經濟層面不管發生什麼。
I'd just say that, look, John and I come from businesses where we've been through these cycles. We know how to operate in a down cycle. We run a business that way. This is a growth business, and we'll treat it as a growth business, but we're responsible from a standpoint of making sure that we adjust this business to whatever economic conditions that we see out there.
我只想說,你看,John 和我都來自曾經歷這些週期的企業。我們知道如何在下行週期中運作。我們就是以那種方式經營業務。這是一門成長型業務,我們會把它當作成長型業務來對待,但從確保我們能把這門業務調整到外部所見的任何經濟環境的角度來看,我們是負責任的。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And as a result, we've been able to make these adjustments. We're fortunate as a company to have the cash position, the balance sheet that we have and all these other. And in the end, you know the story, we have a huge opportunity to be able to grow. You just have this in our way. And like Joe said, and what many others say is it could get worse. We have to be able to be able to balance those short-term worse to with our long-term goal of being able to make Invisalign the standard of care. And that's what we're balancing right now, and that could play out -- that will play out in the next -- whatever, a year to 18 months, things will evolve.
因此,我們才能做出這些調整。作為一家公司,我們很幸運擁有目前的現金部位、資產負債表以及其他各方面。最終,你知道這個故事:我們有巨大的成長機會,只是眼前有一些阻礙。就像 Joe 說的、也像許多人說的那樣,情況可能會更糟。我們必須能夠在短期可能更糟的情況與我們長期目標——讓 Invisalign 成為照護標準——之間取得平衡。這就是我們現在正在權衡的事情,而這可能會在接下來——不管是一年到 18 個月——逐步展開,情勢會演變。
We hope that the economies improve. We hope that a lot of this has just got a short term and things get better. And when things do get better, we're well positioned to be able to grow into this market, but we just have to be based on the realities of what's happening in short term.
我們希望經濟改善。我們希望這些很多都只是短期因素,情況會變好。而當情況真的變好時,我們已經處於有利位置,能在這個市場中成長,但我們必須立足於短期正在發生事情的現實。
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
Great. And a quick follow-up, if I can. On 1Q, you kind of gave some comments on pacing through the quarter, and gave some comments on April as it relates to March. Kind of get the sense that things probably slowed down at the end of 2Q little bit in June, both between FX and China lockdowns being worse. Any sense you can give on sort of the progression through the course of 2Q? And just any early signs you've seen from July, again, realize that walk-down in China and FX is playing a big role. But maybe if you could just focus on America's trends through the quarter, and July. That will be helpful.
很好。我可以再快速追問一下嗎?關於 1Q,你們對季度內的節奏做了一些評論,也談到 4 月相對於 3 月的情況。我有種感覺,2Q 末在 6 月可能稍微放緩了一點,既有匯率(FX)因素,也有中國封控更嚴重的影響。你們能否談談 2Q 期間整體進展的脈絡?以及你們從 7 月看到的任何早期跡象——我也理解中國逐步解封與匯率在其中扮演很大角色。但也許你們可以只聚焦在美洲在季度內以及 7 月的趨勢,這會很有幫助。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Yes. No, it's a good question. So if you think like an overall picture, you hit some of the FX and so on, you look -- everybody can look at FX rates and see the changes and so on, you can project based on those. When you talk about a COVID lockdown or talk specifically in China, there was an impact for us. And we've seen that in the first quarter, we saw it in the second quarter, but it's -- happens in China. It happens in every place that we see where there's a lockdown, we have a reduction in volume. When that lockdown goes away, the volume starts to come back.
是的。不,這是個好問題。所以如果你從整體角度來看,你提到了一些匯率等因素——大家都可以看匯率水準並看到變化,你也可以基於那些變化做推算。當你談到 COVID 封控,或特別談到中國時,對我們確實有影響。我們在第一季度看到了,在第二季度也看到了。但——這發生在中國;也發生在我們看到任何有封控的地方:我們的量就會下降。當封控解除後,量就會開始回來。
So I would say when you think of China, as you go from lockdown to not lockdown, that's favorable for us. We start to see some of the volume come back. And I think when you look at -- I think part of your question is around the U.S. I think what do you see for the U.S. is it's -- maybe things stabilizing a little bit more. You're not seeing -- maybe it's pretty similar to what we exited Q2 into Q3. And I think when you look at the teen benefit that ideally comes through with some of the products and programs that we have in teen in the U.S. and other places, but focus on the U.S. We think that's helpful for us as we go from Q2 to Q3.
所以我會說,當你想到中國,從封控到不封控,這對我們是有利的,我們開始看到部分量回來。我想你問題的一部分是在問美國。我認為你在美國看到的是——也許情況更趨於穩定一些。你不會看到——也許它與我們從 Q2 結束進入 Q3 時的狀況相當接近。而且我認為,當你看青少年(teen)業務的利多——理想情況下,會透過我們在美國及其他地區針對青少年的一些產品與方案體現出來,但先聚焦美國——我們認為這在我們從 Q2 走到 Q3 的過程中會對我們有所幫助。
Operator
Operator
We have reached the end of our question-and-answer session. I will now turn the call back over to Shirley Stacy for closing remarks.
我們已經到達問答環節的結束。現在我將把電話交回給 Shirley Stacy 作結語。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you, operator, and thank you, everyone, for joining us today. We look forward to speaking to you at upcoming financial conferences and industry meetings. And if you have any follow-up questions, please contact our Investor Relations team. Have a great day.
謝謝,接線員,也謝謝各位今天加入我們。我們期待在即將到來的財務會議與產業會議上與各位交流。如果你們有任何後續問題,請聯絡我們的投資人關係團隊。祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference, and you may now disconnect your lines at this time. Thank you for your participation.
謝謝。今天的電話會議到此結束,現在各位可以掛線。感謝各位的參與。